Cancers · 2017 · 26 citations · 28 references
MedicineMolecular BiologyOncologyCancer GeneticsMolecular OncologyNeoplasiaAssay ValidationCancer BiomarkersCancer Molecular DiagnosticsCancer Molecular PathologyImmuno-oncology BiomarkersLung CancerAlk Fusion GenesAlk InhibitionAlk Rearrangement TestingAnaplastic Lymphoma Kinase InhibitionAnaplastic Lymphoma Kinase InhibitorsDiagnostic Cut-offsLung Cancer PathologyTranscripts
Patients with lung cancers harboring an activating anaplastic lymphoma kinase (ALK) rearrangement respond favorably to ALK inhibitor therapy. Fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) are validated and widely used screening tests for ALK rearrangements but both methods have limitations. The ALK RGQ RT-PCR Kit (RT-PCR) is a single tube quantitative real-time PCR assay for high throughput and automated interpretation of ALK expression. In this study, we performed a direct comparison of formalin-fixed paraffin-embedded (FFPE) lung cancer specimens using all three ALK detection methods. The RT-PCR test (diagnostic cut-off ΔCt of ≤8) was shown to be highly sensitive (100%) when compared to FISH and IHC. Sequencing of RNA detected full-length ALK transcripts or EML4-ALK and KIF5B-ALK fusion variants in discordant cases in which ALK expression was detected by the ALK RT-PCR test but negative by FISH and IHC. The overall specificity of the RT-PCR test for the detection of ALK in cases without full-length ALK expression was 94% in comparison to FISH and sequencing. These data support the ALK RT-PCR test as a highly efficient and reliable diagnostic screening approach to identify patients with non-small cell lung cancer whose tumors are driven by oncogenic ALK.
28
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Manabu Soda, Young Lim Choi, Munehiro Enomoto et al. · Nature · 2007 · 5.4K citations
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa et al. · New England Journal of Medicine · 2013 · 3.4K citations · Full text
Medicine, Oncology, Pharmacology +15
Ceritinib in <i>ALK</i> -Rearranged Non–Small-Cell Lung Cancer
Alice T. Shaw, Dong-Wan Kim, Ranee Mehra et al. · New England Journal of Medicine · 2014 · 1.5K citations
Medicine, Oncology, Pharmacology +14
Activating mutations in ALK provide a therapeutic target in neuroblastoma
Rani E. George, Takaomi Sanda, Megan Hanna et al. · Nature · 2008 · 892 citations · Full text